Literature DB >> 7334217

Immunogenetic control of experimental collagen-induced arthritis in rats. II. ECIA susceptibility and immune response to type II collagen (CALF) are linked to RT1.

M M Griffiths, C W DeWitt.   

Abstract

The segregation of genes controlling ECIA susceptibility and the level of immune response to native calf type II collagen were determined in the F2 progeny of matings between WF (RT1u/u; ECIA-susceptible; high responders) and LEW.B3 (RT1n/n; ECIA-resistant; low to intermediate responders). RT1n/n F2 progeny showed resistance to ECIA, low skin test reactivity to type II collagen and intermediate levels of IgG anti-collagen antibodies (-log2 of 6.2 +/- 2.6; mean +/- SD, n = 10). RT1u/u and RT1u/n F2 progeny were susceptible to ECIA and were high responders to type II collagen by skin testing and IgG antibody titres (-log2 of 12.1 +/- 1.3, mean +/- SD, n = 26). Although all rats that developed arthritis were also high responders to type II collagen one group of immature F2 progeny, RT1u/u and RT1u/n, showed high anti-collagen immune responses in the absence of detectable arthritis. The data indicate that genes linked to RT1.A control susceptibility to ECIA and at least part of the immune response to native calf type II collagen in WF and LEW.B3 rats.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334217     DOI: 10.1111/j.1744-313x.1981.tb00954.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  11 in total

1.  The immune response of guinea-pigs to type II collagen: poor cross-reactivity with homologous type II collagen accounts for resistance to collagen-induced arthritis.

Authors:  A D Hernandez; M A Cremer; A S Townes; J M Stuart; A H Kang
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

2.  Arthritis induced in rats with adjuvant oil is a genetically restricted, alpha beta T-cell dependent autoimmune disease.

Authors:  R Holmdahl; T J Goldschmidt; S Kleinau; C Kvick; R Jonsson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

3.  Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice.

Authors:  G W Cannon; S McCall; B C Cole; M M Griffiths; L A Radov; J R Ward
Journal:  Agents Actions       Date:  1990-03

4.  Induction of erosive arthritis in mice after passive transfer of anti-type II collagen antibodies.

Authors:  N Loutis; P Bruckner; A Pataki
Journal:  Agents Actions       Date:  1988-12

5.  Effects of gold sodium thiomalate, cyclosporin A, cyclophosphamide, and placebo on collagen-induced arthritis in rats.

Authors:  G W Cannon; S McCall; B C Cole; L A Radov; J R Ward; M M Griffiths
Journal:  Agents Actions       Date:  1993-03

6.  Human HLA-DR beta gene hypervariable region homology in the biobreeding BB rat: selection of the diabetic-resistant subline as a rheumatoid arthritis research tool to characterize the immunopathologic response to human type II collagen.

Authors:  W C Watson; J P Thompson; K Terato; M A Cremer; A H Kang
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

Review 7.  Rheumatoid arthritis: identifying and characterising polymorphisms using rat models.

Authors:  Anthony C Y Yau; Rikard Holmdahl
Journal:  Dis Model Mech       Date:  2016-10-01       Impact factor: 5.758

8.  Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule.

Authors:  K Terato; K A Hasty; M A Cremer; J M Stuart; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

9.  Synergy between adjuvant arthritis and collagen-induced arthritis in rats.

Authors:  J D Taurog; S S Kerwar; R A McReynolds; G P Sandberg; S L Leary; M L Mahowald
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

10.  Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice.

Authors:  Ann-Sofie Hansson; Asa C M Johansson; Rikard Holmdahl
Journal:  Arthritis Res Ther       Date:  2004-08-12       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.